Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

Jason Haffizulla, Harvey Resnick, Aaron Hartman, Stefan Comhaire, Maria Carríon, Matthew Bardin. Presentation Number LB-35, Session 182a: Late Breaker Oral Abstracts - Clinical Virology and Treatment. Saturday, October 22, 2011, 6:30 PM.

About the US Clinical Trial

The clinical trial was conducted in 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season.  624 patients, 12 to 65 years of age, with influenza symptoms were enrolled in the study within 48 hours of symptom onset and received treatment with 300 mg NTZ, 600 mg NTZ or placebo twice daily for 5 days.  Patients who received an influenza vaccine after August 1, 2010 and patients at risk of complications of influenza based upon CDC or IDSA criteria were excluded from participation in the trial. The study was designed according to FDA Guidance and consistent with prior clinical trials of Tamiflu® and Relenza®. The primary efficacy endpoint of the study was time from first dose to alleviation of symptoms (all symptoms absent or mild and remain so for 24 hours).  

Two hundred and fifty-seven (257) of the 624 patients enrolled in the study (41%) had laboratory confirmed influenza infection by RT-PCR or viral culture at baseline. Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008). Median time to alleviation of symptoms was 95.5 hours for the 600 mg dose group compared to 109.1 hours for the 300 mg do
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
(Date:7/11/2014)... disposable medical suppliers call for the biggest share of ... past two decades, the world market for disposable medical ... year), primarily owing to the importance of these products ... market for disposable medical supplies in the world, accounting ... held by Europe with a 29% market share. The ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... Tickets at the Sleep Train Amphitheatre in Wheatland, CA. ... that can compare to what the Sleep Train Amphitheatre can ... events and special attractions over the course of its existence ... the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) will ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... With the arrival of summer, VisitandCare.com today ... and hair transplant procedures, up 80 percent from July ... medical tourism destinations, the company is helping patients take ... achieve the look they have always desired. , ... in the medical tourism industry, VisitandCare.com is comprised of ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... 11 /PRNewswire-FirstCall/ - BELLUS Health Inc. ("BELLUS Health" or ... quarter and first half ended June 30, 2009. All ... US dollars, unless otherwise specified. , For the three-month ... to $12,880,000 ($0.10 per share), compared to a net ...
... Illinois at Chicago College of Medicine researchers have discovered how ... may lead to a more effectively targeted anti-cancer strategy. ... PLoS ONE online, UIC researchers show how a class ... the drugs, ability to inhibit FoxM1 may account for their ...
... WEST PALM BEACH, Fla., Aug. 11 HearUSA (Amex: EAR ... ring aids and hearing care announced today that it is launching ... The program is scheduled to be made available to AARP members in Florida ... in all 50 states and the U.S. territories. , , ...
... , OKLAHOMA CITY, Aug. 11 ... for revenue cycle management solutions for the healthcare industry, ... Financial Services Accreditation Program (FSAP) - Electronic Health Network ... EHNAC FSAP-EHN accreditation demonstrates that the organization meets a ...
... , PALO ALTO, Calif., Aug. 11 Jazz Pharmaceuticals, Inc. ... quarter ended June 30, 2009. , , Total revenues ... the quarter ended June 30, 2008. Revenues for the second quarter included ... in July 2008 and recognized as revenue when the last patient completed ...
... , LAKEWOOD, Colo., Aug. 11 Mesa Laboratories, Inc. ... Directors has declared a regular quarterly cash dividend of 10 cents ... shareholders of record at the close of business on August 28, ... and markets electronic instruments and disposables for industrial, pharmaceutical and medical ...
Cached Medicine News:Health News:BELLUS Health reports results for first half of fiscal 2009 2Health News:BELLUS Health reports results for first half of fiscal 2009 3Health News:BELLUS Health reports results for first half of fiscal 2009 4Health News:BELLUS Health reports results for first half of fiscal 2009 5Health News:BELLUS Health reports results for first half of fiscal 2009 6Health News:BELLUS Health reports results for first half of fiscal 2009 7Health News:BELLUS Health reports results for first half of fiscal 2009 8Health News:BELLUS Health reports results for first half of fiscal 2009 9Health News:BELLUS Health reports results for first half of fiscal 2009 10Health News:BELLUS Health reports results for first half of fiscal 2009 11Health News:BELLUS Health reports results for first half of fiscal 2009 12Health News:BELLUS Health reports results for first half of fiscal 2009 13Health News:BELLUS Health reports results for first half of fiscal 2009 14Health News:BELLUS Health reports results for first half of fiscal 2009 15Health News:BELLUS Health reports results for first half of fiscal 2009 16Health News:BELLUS Health reports results for first half of fiscal 2009 17Health News:BELLUS Health reports results for first half of fiscal 2009 18Health News:BELLUS Health reports results for first half of fiscal 2009 19Health News:BELLUS Health reports results for first half of fiscal 2009 20Health News:BELLUS Health reports results for first half of fiscal 2009 21Health News:BELLUS Health reports results for first half of fiscal 2009 22Health News:BELLUS Health reports results for first half of fiscal 2009 23Health News:BELLUS Health reports results for first half of fiscal 2009 24Health News:BELLUS Health reports results for first half of fiscal 2009 25Health News:BELLUS Health reports results for first half of fiscal 2009 26Health News:BELLUS Health reports results for first half of fiscal 2009 27Health News:BELLUS Health reports results for first half of fiscal 2009 28Health News:Finding may explain anti-cancer activity of thiazole antibiotics 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 4Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 2Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 3Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 2Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 3
... meridianEMR is a revolutionary "blended model ... patient medical records in your office and ... team of physicians and software engineers, meridianEMR ... to create a highly modular medical EMR ...
... OB/GYN, ER/Trauma, ICC/CCU, woundcare and burn ... precision and control, plus consistent high ... SATIN PLUS* Sterile Singles deliver all ... provides excellent tactile sensitivity. The gloves ...
... Polymed has become even better. Polymed® TLC latex ... Polymed with the exciting addition of vitamin E. ... which are vital to healthy skin. Polymed TLC ... reduce the potential for latex sensitization. The lightly ...
... Clear View Drapes allow practitioners ... patient's leg during intraoperative adjustments. Makes ... and access legholder adjustment handles for ... tear even when controls are adjusted ...
Medicine Products: